PA8471201A1 - Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea - Google Patents
Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroideaInfo
- Publication number
- PA8471201A1 PA8471201A1 PA19998471201A PA8471201A PA8471201A1 PA 8471201 A1 PA8471201 A1 PA 8471201A1 PA 19998471201 A PA19998471201 A PA 19998471201A PA 8471201 A PA8471201 A PA 8471201A PA 8471201 A1 PA8471201 A1 PA 8471201A1
- Authority
- PA
- Panama
- Prior art keywords
- compositions
- parathyroid hormone
- selective
- combinations including
- therapeutic combinations
- Prior art date
Links
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 title abstract 2
- 239000000199 parathyroid hormone Substances 0.000 title abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 208000001164 Osteoporotic Fractures Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
ESTA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS DE COMBINACIONES SINERGICAS Y A PROCEDIMIENTOS QUE COMPRENDEN (-)-CIS-6-FENIL-5- (4-(2-PIRROLIDIN-1-Il-ETOXI)-FENIL -5,6,7,8-TETRAHIDRONAFTALEN-2-OL, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES Y HORMONA PARATIROIDEA, O UNO DE SUS FRAGMENTOS BIOLOGICAMENTE ACTIVOS, A PROCEDIMIENTOS PARA USAR DICHAS COMPOSICIONES Y A ESTUCHES QUE CONTIENEN DICHAS COMPOSICIONES. LAS COMPOSICIONES SON UTILES PARA TRATAR FRAGILIDAD MUSCULO ESQUELETICA, INCLUYENDO OSTEOPOROSIS, FRACTURA OSTEOPOROTICA, MASA OSEA REDUCIDA Y FRAGILIDAD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8947998P | 1998-06-16 | 1998-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8471201A1 true PA8471201A1 (es) | 2000-09-29 |
Family
ID=22217879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA19998471201A PA8471201A1 (es) | 1998-06-16 | 1999-04-29 | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6132774A (es) |
| EP (1) | EP1094808A1 (es) |
| JP (1) | JP2002518323A (es) |
| KR (1) | KR20010052818A (es) |
| CN (1) | CN1305373A (es) |
| AP (1) | AP9901580A0 (es) |
| AR (1) | AR018867A1 (es) |
| AU (1) | AU3725999A (es) |
| BG (1) | BG105125A (es) |
| BR (1) | BR9911228A (es) |
| CA (1) | CA2335078A1 (es) |
| CO (1) | CO5070584A1 (es) |
| EA (1) | EA200001199A1 (es) |
| GT (1) | GT199900066A (es) |
| HN (1) | HN1999000063A (es) |
| HR (1) | HRP20000858A2 (es) |
| HU (1) | HUP0102759A3 (es) |
| ID (1) | ID26873A (es) |
| IL (1) | IL139588A0 (es) |
| IS (1) | IS5719A (es) |
| MA (1) | MA26649A1 (es) |
| NO (1) | NO20006313D0 (es) |
| NZ (1) | NZ508039A (es) |
| OA (1) | OA11566A (es) |
| PA (1) | PA8471201A1 (es) |
| PE (1) | PE20000644A1 (es) |
| PL (1) | PL344982A1 (es) |
| SK (1) | SK18922000A3 (es) |
| TN (1) | TNSN99119A1 (es) |
| TR (1) | TR200003567T2 (es) |
| UA (1) | UA60367C2 (es) |
| WO (1) | WO1999065482A1 (es) |
| YU (1) | YU75800A (es) |
| ZA (1) | ZA993972B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
| US20030191096A1 (en) * | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
| BRPI0416639A (pt) | 2003-11-19 | 2007-01-16 | Metabasis Therapeutics Inc | tiromiméticos contendo fósforo |
| MX2007005137A (es) * | 2004-11-23 | 2007-06-22 | Warner Lambert Co | Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia. |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US8404896B2 (en) | 2006-12-01 | 2013-03-26 | Bristol-Myers Squibb Company | N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| TW201043595A (en) * | 2009-03-13 | 2010-12-16 | Organon Nv | Tetrahydronaphthalen-2-ol derivatives |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| CN111067907A (zh) * | 2018-10-18 | 2020-04-28 | 常州大学 | 孕激素在抑制血管内皮生长因子表达中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254595A (en) * | 1988-12-23 | 1993-10-19 | Elf Sanofi | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them |
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
-
1999
- 1999-04-29 PA PA19998471201A patent/PA8471201A1/es unknown
- 1999-05-03 HN HN1999000063A patent/HN1999000063A/es unknown
- 1999-05-10 GT GT199900066A patent/GT199900066A/es unknown
- 1999-05-26 JP JP2000554362A patent/JP2002518323A/ja active Pending
- 1999-05-26 TR TR2000/03567T patent/TR200003567T2/xx unknown
- 1999-05-26 UA UA2000127244A patent/UA60367C2/uk unknown
- 1999-05-26 EA EA200001199A patent/EA200001199A1/ru unknown
- 1999-05-26 YU YU75800A patent/YU75800A/sh unknown
- 1999-05-26 CN CN99807345A patent/CN1305373A/zh active Pending
- 1999-05-26 PL PL99344982A patent/PL344982A1/xx unknown
- 1999-05-26 ID IDW20002626A patent/ID26873A/id unknown
- 1999-05-26 EP EP99919491A patent/EP1094808A1/en not_active Withdrawn
- 1999-05-26 IL IL13958899A patent/IL139588A0/xx unknown
- 1999-05-26 OA OA1200000340A patent/OA11566A/en unknown
- 1999-05-26 CA CA002335078A patent/CA2335078A1/en not_active Abandoned
- 1999-05-26 NZ NZ508039A patent/NZ508039A/xx unknown
- 1999-05-26 WO PCT/IB1999/000949 patent/WO1999065482A1/en not_active Application Discontinuation
- 1999-05-26 BR BR9911228-0A patent/BR9911228A/pt not_active IP Right Cessation
- 1999-05-26 HU HU0102759A patent/HUP0102759A3/hu unknown
- 1999-05-26 SK SK1892-2000A patent/SK18922000A3/sk unknown
- 1999-05-26 US US09/424,010 patent/US6132774A/en not_active Expired - Fee Related
- 1999-05-26 AU AU37259/99A patent/AU3725999A/en not_active Abandoned
- 1999-05-26 KR KR1020007014141A patent/KR20010052818A/ko not_active Application Discontinuation
- 1999-06-10 AP APAP/P/1999/001580A patent/AP9901580A0/en unknown
- 1999-06-14 PE PE1999000526A patent/PE20000644A1/es not_active Application Discontinuation
- 1999-06-15 TN TNTNSN99119A patent/TNSN99119A1/fr unknown
- 1999-06-15 ZA ZA9903972A patent/ZA993972B/xx unknown
- 1999-06-15 AR ARP990102846A patent/AR018867A1/es not_active Application Discontinuation
- 1999-06-15 MA MA25623A patent/MA26649A1/fr unknown
- 1999-06-16 CO CO99037623A patent/CO5070584A1/es unknown
-
2000
- 2000-11-21 IS IS5719A patent/IS5719A/is unknown
- 2000-12-12 NO NO20006313A patent/NO20006313D0/no not_active Application Discontinuation
- 2000-12-14 HR HR20000858A patent/HRP20000858A2/hr not_active Application Discontinuation
-
2001
- 2001-01-08 BG BG105125A patent/BG105125A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8471201A1 (es) | Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea | |
| TR199800767T2 (xx) | Proteaz engelleyicileri. | |
| HN1999000210A (es) | Composiciones de celecoxib | |
| NO20040331L (no) | Legemidler for sykdommer med benmassetap som har Eragonist som den aktive bestanddel | |
| GT200100238AA (es) | Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis (solicitud fraccionaria # 1 derivada de lapi-2001-0238) | |
| DK1425035T3 (da) | Anvendelse af biologisk aktiv HIV-1 Tat, fragmenter eller derivater deraf til targeting og/eller aktivering af antigen-præsenterende celler og/eller til afgivelse af cargo molekyler til forebyggende eller terapeutisk vaccination og/eller til behandling.. | |
| BR0111237B1 (pt) | implante para um osso e aparelho osteosintÉtico para fixaÇço de um émero fraturado. | |
| CO4890856A1 (es) | CICATRIZACION DE FRACTURAS USANDO ANALOGOS DE PTHrP | |
| BR9714155A (pt) | Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina. | |
| ES2136828T3 (es) | Dispositivo ortopedico accionado por el paciente. | |
| NZ547930A (en) | Set of osteosynthesis plates | |
| FR06C0032I2 (fr) | Formulations proteiniques | |
| NO20060808L (no) | Andvendelse av en PAK-inhibitorer for behandling av en leddsykdom | |
| AR049876A1 (es) | Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos | |
| GT199800083A (es) | Agonistas de prostaglandinas. | |
| EA200600228A1 (ru) | Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов | |
| BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
| ES2116642T3 (es) | Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol. | |
| ATE438618T1 (de) | Inhibitoren von humanem adam-10 | |
| AR044775A1 (es) | Composiciones farmaceuticas de atorvastatina | |
| ID18079A (id) | Komposisi farmasi yang mengandung bahan pemercepat osteogenesis | |
| DE60233803D1 (de) | 5-cnac zur oralen verabreichung von parathormonfragmenten | |
| PA8475901A1 (es) | Terapia de combinacion para la fragilidad musculoesqueletica | |
| BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
| BR0203267A (pt) | Combinações farmacêuticas para o tratamento de doenças neurodegenerativas |